Tricida, Inc.

OTCPK:TCDA.Q Aktierapport

Börsvärde: US$580.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Tricida Förvaltning

Förvaltning kriterier kontrolleras 3/4

Tricida VD är Gerrit Klaerner, utsedd i Aug 2013, har en mandatperiod på 9.83 år. totala årliga ersättningen är $ 4.68M, bestående av 12.8% lön 87.2% bonusar, inklusive företagsaktier och optioner. äger direkt 0.68% av företagets aktier, värda $ 3.93. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 4 år respektive 9.5 år.

Viktig information

Gerrit Klaerner

Verkställande direktör

US$4.7m

Total ersättning

VD-lön i procent12.83%
Anställning som VD9.8yrs
Ägande av VD0.7%
Ledningens genomsnittliga anställningstid4yrs
Styrelsens genomsnittliga mandatperiod9.5yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Oct 19

Tricida enters $125M debt facility

Tricida (NASDAQ:TCDA) gets into a debt facility of $125M with Hercules Capital, provider of customized debt financing for companies in the life sciences and technology-related markets. Of the $125M, $100M will be available for drawdown at Tricida’s option subject to the achievement of certain milestones. Under the terms of the debt facility, $25M will be available for drawdown until December 31, 2022, subject to the announcement of positive data from the VALOR-CKD trial.  An additional $25M will be available for drawdown until the earlier of ten business days following the filing of the NDA for veverimer and September 15, 2023. An additional $50M will be available for drawdown until the earlier of ten business days following the FDA approval of veverimer and February 15, 2024. The loans bear interest at a floating per annum interest rate equal to the greater of either 8.75% or the lesser of 8.75% plus the prime rate as reported in The Wall Street Journal minus 6.25% and 10.25%.
Seeking Alpha • Sep 21

Tricida: Important Binary Event Coming Up

Summary TCDA has a major binary event next month. Data from VALOR may turn out well given the logic behind early trial termination, prior data and so on. There could be some quick upside in the next 30 odd days. Tricida (TCDA) has been doing wonderfully lately, over the last 12 months, but it is down considerably from its PDUFA highs. That was from two years ago, when I used to cover the stock. I recall buying some TCDA, making good money, and then losing some money on the shares I held on to, because their lead asset veverimer was handed a CRL. The stock is up these days not because the CRL was resolved, but because of a number of other small and large things. Let's first discuss the CRL, though. Then we will see what has been responsible for the stock’s sudden buoyancy. Veverimer is targeting metabolic acidosis in CKD or chronic kidney disease patients. In an earlier trial, after 12 weeks of treatment, TRC101 or veverimer was able to increase blood bicarbonate level of at least 4 milliequivalents per liter (mEq/L) or achieved a blood bicarbonate level in the normal range of 22 to 29 mEq/L in 59.2% patients, compared with 22.5% of them in the placebo group (p< 0.0001). However, one of veverimer’s major problem is the standardly used therapy for this indication, which you can buy in a bottle from a grocery store for a few bucks. This is bicarbonate of soda, and while there have been no industry-sponsored trials for obvious reasons, it has long been used by doctors to treat metabolic acidosis. Its problem is that too much sodium content in the blood can cause heart diseases, which is where veverimer has a great deal of utility with its completely different mechanism of action. However, the FDA was not convinced, and it issued a CRL, asking for, among other things: Additional data regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate. Whether the demonstrated effect size would be reasonably likely to predict clinical benefit. I discussed all this in an earlier article from two years ago. A summary of the CRL from the company management was here: “According to the CRL, the FDA is seeking additional data beyond the TRCA-301 and TRCA-301E trials regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate and the applicability of the treatment effect to the U.S. population. FDA also expressed concern as to whether the demonstrated effect size would be reasonably likely to predict clinical benefit,” Tricida said. This was an accelerated approval, and the company was already conducting VALOR-CKD at that time as a confirmatory trial. After the CRL, they said that interim data from this trial could be used to provide the data required by the FDA. This trial was supposed to enroll ~1500 patients and topline in 2023-24. In May, the company did an “administrative stop” to this trial after enrolling 1480 patients last year, and after 237 patients reached a primary endpoint event — end-stage renal disease, renal death, or greater than or equal to 40% reduction in eGFR or estimated glomerular filtration rate — in the renal outcomes study. This was done to conserve their cash reserve, which will be near depleted this quarter. Moreover, the FDA seems to have agreed that this may work. As Phil Nadeau at Cowen explained: Assuming a true hazard ratio ((HR)) of 0.70, the trial would be 78% powered at 250 events. Switching from power to observed HR, VALOR-CKD could be successful at 250 events if the observed HR is 0.78. There is only a modest increase to 0.79 observed HR should 300 events be in the final analysis. This calculation on the observed HR required for significance is based on 300 simulations on trial outcomes.
Analysartikel • Sep 14

Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)

Today we will run through one way of estimating the intrinsic value of Tricida, Inc. ( NASDAQ:TCDA ) by estimating the...
Analysartikel • Dec 14

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

Investors who take an interest in Tricida, Inc. ( NASDAQ:TCDA ) should definitely note that the CFO & Executive VP...

Analys av ersättningar till VD

Hur har Gerrit Klaerner:s ersättning förändrats jämfört med Tricida:s resultat?
DatumTotal ersättningLönFöretagets resultat
Sep 30 2022n/an/a

-US$134m

Jun 30 2022n/an/a

-US$148m

Mar 31 2022n/an/a

-US$153m

Dec 31 2021US$5mUS$600k

-US$177m

Sep 30 2021n/an/a

-US$181m

Jun 30 2021n/an/a

-US$219m

Mar 31 2021n/an/a

-US$244m

Dec 31 2020US$9mUS$598k

-US$265m

Sep 30 2020n/an/a

-US$268m

Jun 30 2020n/an/a

-US$235m

Mar 31 2020n/an/a

-US$213m

Dec 31 2019US$10mUS$584k

-US$177m

Sep 30 2019n/an/a

-US$146m

Jun 30 2019n/an/a

-US$131m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$1mUS$503k

-US$103m

Sep 30 2018n/an/a

-US$96m

Jun 30 2018n/an/a

-US$77m

Mar 31 2018n/an/a

-US$60m

Dec 31 2017US$821kUS$425k

-US$41m

Ersättning vs marknad: Gerrit s total kompensation ($USD 4.68M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 655.15K ).

Ersättning vs inkomst: Ersättningen från Gerrit har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Gerrit Klaerner (51 yo)

9.8yrs
Anställning
US$4,676,490
Kompensation

Dr. Gerrit Klaerner, Ph.D. Founded Tricida, Inc.and has been its Chief Executive Officer and President since August 2013 and has been its an Executive Director since July 2013. Dr. Klaerner was the Founder...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Gerrit Klaerner
Founder9.8yrsUS$4.68m0.68%
$ 3.9
Geoffrey Parker
COO, CFO & Executive VP6.2yrsUS$2.51m0.72%
$ 4.2
Robert McKague
Executive VP3.3yrsUS$2.43m0.031%
$ 0.2
Dawn Parsell
Executive Vice President of Clinical Development4.8yrsUS$2.77m0.0060%
$ 0.03
Annie Yoshiyama
VP of Finance & Chief Accounting Officer2.5yrsinga uppgifteringa uppgifter
Jackie Cossmon
Vice President of Investor Relations & Communicationsno datainga uppgifteringa uppgifter
Edward Hejlek
Executive Vice President of Intellectual Property3.3yrsUS$2.10minga uppgifter
4.0yrs
Genomsnittlig anställningstid
58yo
Genomsnittlig ålder

Erfaren ledning: TCDA.Q s ledningsgrupp anses vara erfaren ( 4 års genomsnittlig anställningstid).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Gerrit Klaerner
Founder9.9yrsUS$4.68m0.68%
$ 3.9
Kathryn Falberg
Independent Non-Employee Director5.1yrsUS$329.00k0.074%
$ 0.4
Klaus Veitinger
Independent Chairman of the Board9.3yrsUS$379.00k0.20%
$ 1.1
David Hirsch
Independent Non-Employee Director6.9yrsUS$326.50k0.019%
$ 0.1
Robert Alpern
Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board9.7yrsUS$314.00kinga uppgifter
John Fordtran
Member of Scientific & Clinical Advisory Boardno datainga uppgifteringa uppgifter
David Bushinsky
Member of Scientific & Clinical Advisory Boardno datainga uppgifteringa uppgifter
Craig Hawker
Member of Scientific & Clinical Advisory Boardno datainga uppgifteringa uppgifter
Sandra Coufal
Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board9.9yrsUS$316.50k0.15%
$ 0.9
Navdeep Tangri
Member of Scientific & Clinical Advisory Boardno datainga uppgifteringa uppgifter
Thomas Hostetter
Member of Scientific & Clinical Advisory Boardno datainga uppgifteringa uppgifter
Bertram Pitt
Member of Scientific and Clinical Advisory Boardno datainga uppgifteringa uppgifter
9.5yrs
Genomsnittlig anställningstid
60yo
Genomsnittlig ålder

Erfaren styrelse: TCDA.Q s styrelse anses vara erfaren ( 9.5 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2023/06/13 10:46
Aktiekurs vid dagens slut2023/06/13 00:00
Intäkter2022/09/30
Årlig intjäning2021/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Tricida, Inc. bevakas av 3 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Dana FlandersGoldman Sachs
Jessica FyeJ.P. Morgan
Philip NadeauTD Cowen